The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2503 and HCP1306 in healthy volunteers.
Age 19~64 years in healthy volunteers
18 kg/m² ≤ BMI ≤ 30 kg/m², weight(men) ≥55kg / weight(women) ≥45kg
Agrees that the person, spouse, or partner uses appropriate medically recognized contraception and does not provide sperm or eggs from the date of administration of the first investigational drug to 14 days after the administration of the last investigational drug
Subjects who voluntarily decides to participate in this clinical trial and agree in writing to ensure compliance with the clinical trial
Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study
Subjects who judged ineligible by the investigator
Crossover
HIP2503
DrugTake 1 orally disintegrating tablet once per period
HCP1306
DrugTake 1 tablet once per period
AUCt
Pharmacokinetic evaluation
Cmax
Pharmacokinetic evaluation
Ka
Pharmacokinetic evaluation
Concentration/Cmax_%
Pharmacokinetic evaluation
AUCinf
Pharmacokinetic evaluation
AUCt/AUCinf
Pharmacokinetic evaluation
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
